Australia markets open in 1 hour 59 minutes

XORTX Therapeutics Inc. (XRTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.8100-0.0300 (-1.63%)
At close: 03:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.8400
Bid1.7700 x 1000
Ask1.8200 x 1100
Day's range1.7500 - 1.8400
52-week range1.7300 - 5.8900
Avg. volume1,080,558
Market cap23.123M
Beta (5Y monthly)0.24
PE ratio (TTM)N/A
EPS (TTM)-1.0540
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Nanalysis Announces the Closing of Acquisition of K'(Prime) Technologies Inc.

    Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1) ("Nanalysis" or the "Company") is pleased to announce that it has successfully closed the previously announced acquisition of K'(Prime) Technologies Inc. (KPrime), a North American sales and service company, with a particular focus on scientific instrumentation for pharma, food, chemical and oil & gas customers, as well as imaging systems for security applications.

  • GlobeNewswire

    XORTX to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

    CALGARY, Alberta, Jan. 10, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10th through 13th, 2022. At the conference, Dr. Allen Davidoff, XORTX’s CEO will provide an update on the Company w

  • PR Newswire

    Nanalysis Establishes Scientific Advisory Board with Four World Renowned Scientists

    Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1) ("Nanalysis" or the "Company") is pleased to announce that, effective December 21, 2021, it has established a Scientific Advisory Board, with four world renowned scientists as founding members, including Dr. Matt Rosen of Harvard Medical School and co-founder of Hyperfine.